

## MagForce AG to participate in nine upcoming international conferences in H2 2018

**Berlin, Germany and Nevada, USA, September 3, 2018** - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced its participation in nine upcoming scientific and investor conferences in the second half of 2018:

- **German Fall Conference**  
Date: September 3-4, 2018  
Location: Frankfurt, Germany  
Presentation: Christian von Volkmann, CFO of MagForce AG, Tuesday, September 4, 2018
- **Goldman Sachs European Medtech and Healthcare Conference**  
Date: September 5-6, 2018  
Location: London, UK  
Presentation: Ben J. Lipps, CEO of MagForce AG, Thursday, September 6, 2018
- **Berenberg & Goldman Sachs Seventh German Corporate Conference**  
Date: September 24-26, 2018  
Location: Munich, Germany  
Presentation: Ben J. Lipps, CEO of MagForce AG, Tuesday, September 25, 2018
- **13th Meeting of the European Association of Neuro-Oncology (EANO 2018)**  
Date: October 10-14, 2018  
Location: Stockholm, Sweden
- **18th European Congress of Neurosurgery (EANS 2018)**  
Date: October 21-25, 2018  
Location: Brussels, Belgium  
Booth: No. 12  
Lunch Symposium: *"Local Therapies For Malignant Gliomas"*  
Speakers: Prof Dr Walter Stummer, Director of the Department of Neurosurgery at the University Hospital Muenster, Germany;  
Colin Watts, MD PHD, University of Birmingham, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, Birmingham, Great Britain  
Date & Time: Golden Hall, Tuesday, October 23, 2018; 1.15-2.15pm CEST

Corporate News | 03. September 2018

- **MEDICA 2018**  
Date: November 12-15, 2018  
Location: Düsseldorf, Germany  
Community booth: Berlin Partner für Wirtschaft und Technologie GmbH No. F 42, hall 15
- **23rd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO)**  
Date: November 15-18, 2018  
Location: New Orleans, Louisiana, USA
- **German Equity Forum 2018**  
Date: November 26-28, 2018  
Location: Frankfurt, Germany  
Presentation: Ben J. Lipps, CEO of MagForce AG, Tuesday, November 27, 2018
- **Prior Capital Market Conference**  
Date: December 4, 2018  
Location: Dreieich, Germany  
Presentation: Barbara von Frankenberg, Vice President Communications & Investor Relations of MagForce AG, Tuesday, December 4, 2018

#### **About MagForce AG and MagForce USA, Inc.**

MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm<sup>®</sup> therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm<sup>®</sup>, NanoPlan<sup>®</sup>, and NanoActivator<sup>®</sup> are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

#### **Disclaimer**

*This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may*

Seite 2 von 3

*substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.*